ライフサイエンスコーパス: diuretic therapy

1 ht provide insightful information to titrate diuretic therapy.

2 ion or improved renal function when added to diuretic therapy.

3 f changes observed following paracentesis or diuretic therapy.

4 ment of acute decompensated heart failure is diuretic therapy.

5 according to the need for intensification of diuretic therapy.

6 is followed by colloid volume expansion, and diuretic therapy.

7 e especially likely to benefit from low-dose diuretic therapy.

8 s; nocturia can be more safely alleviated by diuretic therapy.

9 body weight, despite the use of intravenous diuretic therapy.

10 dical management with heart rate control and diuretic therapy.

11 ven by the lack of reliable tools to titrate diuretic therapy.

12 f-concept that the NRPE can be used to guide diuretic therapy.

13 atrial fibrillation, pacemakers, and chronic diuretic therapy.

14 ventricular function, renal impairment, and diuretic therapy (adjusted hazard ratio: 3.00; 95% confi

15 background diuretic treatment and change in diuretic therapy after randomization to dapagliflozin or

16 d pharmacological treatment for AHF includes diuretic therapy aiming to relieve congestion and achiev

17 n may allow for less intensification of loop diuretic therapy and a lower incidence of worsening rena

18 udy, lower-extremity edema responded to oral diuretic therapy and did not seem to be associated with

19 increased NT-proBNP as guidance to increase diuretic therapy and reduce the GRMT up-titration rate,

20 ological principles that underlie the use of diuretic therapy and the available data on the optimal u

21 acy of dapagliflozin according to background diuretic therapy and the influence of dapagliflozin on l

22 Sodium retention required diuretic therapy, and mild hypocalcemia and hyperphospha

23 bsence of HF history, HF signs and symptoms, diuretic therapy, and plasma cell dyscrasia with evidenc

24 ave sufficient fluid accumulation to mandate diuretic therapy but are often resistant to diuresis.

25 cardiovascular risk factors, was specific to diuretic therapy but not present for other major antihyp

26 fluid restriction and individually adjusted diuretic therapy by either continuous or bolus infusions

27 ia, or an inadequate response to traditional diuretic therapy despite dose escalation.

28 or mortality benefit from the use of chronic diuretic therapy, diuretics rapidly improve symptoms ass

29 E, and this information can be used to guide diuretic therapy during acute decompensated heart failur

30 ous ultrafiltration and standard intravenous diuretic therapy for hypervolemic heart failure (HF) pat

31 ltrafiltration is an alternative strategy to diuretic therapy for the treatment of patients with acut

32 The findings were similar for high-dose diuretic therapy (for stroke, RR, 0.49; 95% CI, 0.39-0.6

33 hour intervals, in addition to combinational diuretic therapy in approximately 70% and both oral spir

34 The addition of acetazolamide to loop diuretic therapy in patients with acute decompensated he

35 rs may result in interaction with background diuretic therapy in patients with heart failure and pres

36 italization events (eg, need for intravenous diuretic therapy in the emergency or outpatient setting)

37 Early addition of empagliflozin to standard diuretic therapy increases urine output without affectin

38 een hospitalized or had received intravenous diuretic therapy is unclear.

39 nt systolic and diastolic pressures, and for diuretic therapy, losartan-based therapy was associated

40 atory drugs, fluid management with effective diuretic therapy might be needed.

41 stable after esophageal variceal banding or diuretic therapy of ascites.

42 The effect of diuretic therapy on arrhythmic death in patients with le

43 this genetic variant modifies the effect of diuretic therapy on the incidence of myocardial infarcti

44 , and those requiring outpatient intravenous diuretic therapy only for worsening HF (without HFH) in

45 ection fraction had outpatient escalation of diuretic therapy over longitudinal follow-up, and these

46 , to 23 of the 93 patients (25%) on ACEI and diuretic therapy (p=0.001) and to 18 of the 46 patients

47 o 18 of the 42 patients (19%) on digoxin and diuretic therapy (p=0.009), to 23 of the 93 patients (25

48 nd chloride excretion, creatinine clearance, diuretic therapy, pH, known diabetes and intensive care

49 Low-dose diuretic therapy prevented not only stroke (RR, 0.66; 95

50 Symptomatic improvement with diuretic therapy supports the presence of HFpEF in patie

51 3) randomized to protocol-driven intensified diuretic therapies, the mean diuretic-induced natriuresi

52 of adults with cirrhosis who were receiving diuretic therapy, the findings suggest that SGLT-2 inhib

53 f metrics of renal function and preadmission diuretic therapy, traditional baseline characteristics,

54 Combination diuretic therapy using any of several thiazide-type diur

55 toms or in the change in renal function when diuretic therapy was administered by bolus as compared w

56 ciation of empagliflozin use with changes in diuretic therapy was also studied.

57 In carriers of the adducin variant, diuretic therapy was associated with a lower risk of com

58 385 carriers of the adducin variant allele, diuretic therapy was associated with a lower risk of the

59 carriers of the adducin wild-type genotype, diuretic therapy was not associated with the risk of MI

60 Diuretic therapy was superior to beta-blockade with rega

61 potential utility of pendrin inhibitors for diuretic therapy, we tested in mice a small-molecule pen

62 ting to development of gouty attacks such as diuretic therapy, weight gain, and alcohol consumption m

63 of iBNP levels and the timing of intravenous diuretic therapy were documented.

64 with more advanced kidney disease and/or on diuretic therapy were more likely to experience an 'eGFR

65 ld be managed by modest salt restriction and diuretic therapy with spironolactone or an equivalent in